GlassScriptPhysician profile
Isabel B Rose
NPI 1316609548
$13,498.41
in general payments reported to CMS, 2019-2025
57 companies · $3,717 in 2025
The $3,717 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,671 · 2023: $2,202 · 2024: $5,909 · 2025: $3,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,277 · Consulting Fee: $1,688 · Travel and Lodging: $757 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,276.78 |
| Consulting Fee | $1,687.50 |
| Travel and Lodging | $757.08 |
| Education | $105.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,816.00 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $990.05 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $831.79 | 2022-2025 | Calquence, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $829.53 | 2022-2025 | Opdivo, Reblozyl, Eliquis |
| Janssen Biotech, INC. | $822.75 | 2023-2025 | Erleada, Rybrevant, Darzalex |
| Pfizer INC. | $658.01 | 2022-2025 | |
| Genentech USA, INC. | $382.44 | 2022-2025 | Polivy, Itovebi, Lunsumio |
| Sobi, INC | $365.08 | 2022-2025 | |
| Daiichi Sankyo INC. | $347.30 | 2022-2025 | Enhertu, Injectafer |
| Incyte Corporation | $346.84 | 2022-2025 | Jakafi, Niktimvo, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $320.09 | 2022-2025 | Vpriv, Ninlaro, Alunbrig |
| Glaxosmithkline, LLC. | $316.04 | 2022-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $296.08 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Bayer Healthcare Pharmaceuticals INC. | $289.55 | 2022-2025 | |
| Seagen INC. | $280.92 | 2022-2023 | Adcetris, Tivdak, Padcev |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $241.96 | 2022-2023 | Blincyto, Kyprolis, Lumakras |
| Lilly USA, LLC | $237.54 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Gilead Sciences, INC. | $178.91 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $175.82 | 2023-2025 | Libtayo, Lynozyfic |
| Exelixis INC. | $174.96 | 2023-2025 | Cabometyx |
| Eisai INC. | $164.96 | 2022-2025 | |
| Astellas Pharma US INC | $161.36 | 2022-2025 | Padcev, Xtandi, Vyloy |
| Beigene USA, INC. | $160.37 | 2023-2024 | Brukinsa |
| Immunocore Limited | $157.56 | 2023-2025 | Kimmtrak |
| Pharmaessentia USA Corporation | $155.58 | 2024-2025 | Besremi |
| Genzyme Corporation | $153.28 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $142.19 | 2022-2025 | Onivyde, Tazverik |
| Beone Medicines USA, INC. | $125.28 | 2025 | Brukinsa, Tevimbra |
| Spectrum Pharmaceuticals INC. | $119.42 | 2023-2025 | Rolvedon |
| Adc Therapeutics America, INC. | $117.09 | 2023-2025 | |
| Mirati Therapeutics, INC. | $102.31 | 2023-2024 | Krazati |
| Syndax Pharmaceuticals, INC. | $99.15 | 2025 | |
| Array Biopharma INC | $68.48 | 2022-2025 | Lorbrena, Xalkori, Braftovi |
| Rigel Pharmaceuticals, INC. | $64.94 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Puma Biotechnology, INC. | $59.31 | 2024 | |
| Alexion Pharmaceuticals, INC. | $59.09 | 2024 | Ultomiris |
| Kite Pharma, INC. | $52.91 | 2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $51.24 | 2025 | Qinlock, Romvimza, Tgct |
| Legend Biotech USA INC. | $50.84 | 2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $48.91 | 2022-2024 | |
| G1 Therapeutics, INC. | $41.95 | 2023 | Cosela |
| Morphosys, US INC. | $41.00 | 2022-2024 | Monjuvi |
| Iovance Biotherapeutics, INC. | $39.84 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $32.87 | 2023-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $32.56 | 2024 | Givlaari |
| Taiho Oncology, INC. | $30.80 | 2023 | |
| Tersera Therapeutics LLC | $29.86 | 2025 | Zoladex |
| Celgene Corporation | $29.70 | 2023 | Pomalyst |
| Pharmacyclics LLC, An Abbvie Company | $28.80 | 2022 | |
| Corcept Therapeutics | $26.60 | 2025 | Korlym |
| Pharmacosmos Therapeutics INC. | $25.68 | 2025 | Monoferric |
| Azurity Pharmaceuticals, INC. | $25.07 | 2025 | Danziten |
| Global Blood Therapeutics, INC. | $24.92 | 2022 | |
| Accord Healthcare, INC. | $23.60 | 2025 | |
| Octapharma USA, INC. | $18.05 | 2023 | Panzyga |
| Caris Mpi, INC. | $17.25 | 2025 | Mi Cancer Seek |
| Acrotech Biopharma INC. | $13.93 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.